Abnormal functioning of the mTOR pathway may contribute to the pathogenesis of some solid tumors, especially renal cell carcinoma (RCC).[1] The mTOR is the molecular target for small molecule inhibitors (i.e., temsirolimus and everolimus), which have demonstrated significant clinical activity in patients with advanced RCC. Here, MTOR is linked to renal cell carcinoma.